| 1179 PERSISTENCE, EFFICACY AND TOLERANCE OF SUBCUTANEOUS INFLIXIMAB AFTER SWITCH FROM INTRAVENOUS INFLIXIMAB IN IBD PATIENTS IN REMISSION:: ONE-TEAR RESULTS FROM A MULTICENTER … N Mathieu, F Heluwaert, P Rivière, X Hebuterne, A Chupin, V Abitbol, ... Gastroenterology 166 (5), S-282, 2024 | | 2024 |
| What is the rate of definitive stoma after subtotal colectomy for inflammatory bowel disease? A nationwide study of 1860 patients J Deyrat, A Challine, T Voron, LV O'Connell, MK Collard, S Tzedakis, ... Colorectal Disease, 2024 | | 2024 |
| Chronic inflammatory proctitis P Seksik Hépato-Gastro & Oncologie Digestive 31 (5), 506-508, 2024 | | 2024 |
| The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial R Lorenzon, C Ribet, F Pitoiset, S Aractingi, B Banneville, L Beaugerie, ... Journal of Autoimmunity 144, 103172, 2024 | 2 | 2024 |
| Lymphoma in Patients with Inflammatory Bowel Disease: A Multicentre Collaborative Study Between GETAID and LYSA M Muller, J Broséus, A Guilloteau, S Wasse, C Thiéblemont, S Nancey, ... Journal of Crohn's and Colitis 18 (4), 533-539, 2024 | | 2024 |
| Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials II Siempos, AC Kalil, D Belhadi, VC Veiga, AB Cavalcanti, ... EClinicalMedicine 69, 2024 | | 2024 |
| What should be done in 2024 in the event of failure of anti-TNF treatment for ano-perineal fistulas in Crohn’s disease? N Fathallah, P Seksik, I Nion-Larmurier, A Alam, V de Parades Hépato-Gastro & Oncologie Digestive 31 (2), 172-180, 2024 | | 2024 |
| Que faire en 2024 en cas d'échec des anti-TNF dans les fistules ano-périnéales de la maladie de Crohn? N Fathallah, P Seksik, I Nion-Larmurier, A Alam, V de Parades Hépato-Gastro & Oncologie Digestive 31 (2), 2024 | | 2024 |
| Persistence, efficacy and tolerance of subcutaneous Infliximab after switch from intravenous infliximab in IBD patients in remission: one-year results from a multicenter … N Mathieu, F Heluwaert, P Riviere, X Hebuterne, A Chupin, V Abitbol, ... JOURNAL OF CROHNS & COLITIS 18, I1645-I1645, 2024 | | 2024 |
| Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study M Andre, J Kirchgesner, D Laharie, L Guillo, L Abramowitz, P Seksik, ... JOURNAL OF CROHNS & COLITIS 18, I1577-I1577, 2024 | | 2024 |
| P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID B Caron, P Seksik, A Buisson, P Wils, G Savoye, C Stefanescu, D Laharie, ... Journal of Crohn's and Colitis 18 (Supplement_1), i1925-i1925, 2024 | | 2024 |
| DOP65 Infliximab plus azathioprine and quick steroids discontinuation versus azathioprine plus steroids in patients with acute severe Ulcerative Colitis responding to … A Amiot, P Seksik, A Meyer, C Stefanescu, P Wils, R Altwegg, L Vuitton, ... Journal of Crohn's and Colitis 18 (Supplement_1), i191-i191, 2024 | 1 | 2024 |
| P857 Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study M Andre, J Kirchgesner, D Laharie, L Guillo, L Abramowitz, P Seksik, ... Journal of Crohn's and Colitis 18 (Supplement_1), i1587-i1587, 2024 | | 2024 |
| P903 Persistence, efficacy and tolerance of subcutaneous Infliximab after switch from intravenous infliximab in IBD patients in remission: one-year results from a multicenter … N Mathieu, F Heluwaert, P Riviere, X Hebuterne, A Chupin, V Abitbol, ... Journal of Crohn's and Colitis 18 (Supplement_1), i1655-i1655, 2024 | | 2024 |
| DOP26 Metagenomic and metabolomic profiles in IBD: understanding microbial and metabolic shifts from a large deeply phenotyped cohort B Marius, N Rolhion, L Creusot, A Lefevre, I Alonso, L Brot, C Danne, ... Journal of Crohn's and Colitis 18 (Supplement_1), i121-i121, 2024 | | 2024 |
| Gut dysbiosis in Crohn's disease: never so close to solving the chicken-and-egg enigma: Commentary to “Gut Microbiome Composition Is Associated with Future Onset of Crohn's … N Grellier, H Sokol, P Seksik Clinics and Research in Hepatology and Gastroenterology, 102272, 2023 | 1 | 2023 |
| Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study … L Guillo, G Savoye, A Amiot, C Gilletta, M Nachury, N Dib, A Bourreille, ... Clinical and translational gastroenterology 14 (12), e00607, 2023 | 1 | 2023 |
| Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID R Al Bacha, Y Bouhnik, M Serrero, J Filippi, X Roblin, A Bourrier, ... Digestive and Liver Disease 55 (12), 1632-1639, 2023 | 4 | 2023 |
| Adalimumab in biologic-naïve patients with Crohn’s disease after resolution of an intra-abdominal abscess: a prospective study from the GETAID Y Bouhnik, GP de Chambrun, J Lambert, M Nachury, P Seksik, R Altwegg, ... Clinical Gastroenterology and Hepatology 21 (13), 3365-3378. e5, 2023 | 3 | 2023 |
| Urbanization associates with restricted gut microbiome diversity and delayed maturation in infants F Morandini, K Perez, L Brot, SM Seck, L Tibère, JP Grill, E Macia, ... Iscience 26 (11), 2023 | 1 | 2023 |
Harry SokolProfessor of Gastroenterology, St Antoine Hospital在 aphp.fr 的电子邮件经过验证
